MRI融合冷冻消融:前后病变有预后差异吗?

IF 2.9 2区 医学 Q1 UROLOGY & NEPHROLOGY
Journal of endourology Pub Date : 2025-03-01 Epub Date: 2025-02-06 DOI:10.1089/end.2024.0720
Lara Rodriguez-Sanchez, Sonya A Lehmann, Michael W Kattan, Alberto Lopez-Prieto, Luis Avila-Moreno, Gloria Egui-Benatuil, Fernando J Bianco
{"title":"MRI融合冷冻消融:前后病变有预后差异吗?","authors":"Lara Rodriguez-Sanchez, Sonya A Lehmann, Michael W Kattan, Alberto Lopez-Prieto, Luis Avila-Moreno, Gloria Egui-Benatuil, Fernando J Bianco","doi":"10.1089/end.2024.0720","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Introduction:</i></b> Cryotherapy pioneered ablation therapy for prostate cancer (PCa), initially using larger ablations. As the technique advanced, a more targeted approach was developed irrespective of lesion location. However, some clinical guidelines have addressed concerns for treating posterior areas. This study evaluates the validity of these concerns. <b><i>Materials and Methods:</i></b> We retrospectively studied 814 Magnetic Resonance Imaging Fusion Target Cryotherapy (MRFTC) treatment-naïve patients with PCa with a single index lesion (2013-2023) under local anesthesia. We grouped by treatment location: anterior, anterior-posterior, and posterior. Disease progression, defined as conversion to radical treatment, initiation of hormonal therapy, or development of metastases, was evaluated with survival analysis via the Kaplan-Meier log-rank test. Univariate and multivariable analyses were employed to compare outcomes among different treatment groups and other risk factors. Functional outcomes were evaluated using the Sexual Health Inventory for Men (SHIM) and International Prostate Symptom Score questionnaires, with comparisons made over time and by lesion location through <i>t</i>-tests. Complication rates were documented across the various treatment areas. <b><i>Results:</i></b> The distribution of patients' characteristics across treatment groups was similar. Procedure pain scores were similar irrespective of lesion location. Five years post-MRFTC, 87%, 89%, and 90% of patients treated for anterior, anterior-posterior, and posterior lesions, respectively, remained progression-free with no significant variation between groups (<i>p</i> = 0.22). For all groups, there were significant improvements in urinary function (baseline vs. 3 months). The posterior group showed a marginal, yet statistically significant negative difference in SHIM scores at 3 months. However, the score recovered by 1 year where no additional significant changes were noted. The most common complication was urinary retention and no cases of rectal fistula were reported. <b><i>Conclusions:</i></b> Our findings challenge clinical guidelines suggesting avoidance of focal cryoablation for posterior lesions. Using MRFTC, cryotherapy has proven to be safe and effective, regardless of lesion location.</p>","PeriodicalId":15723,"journal":{"name":"Journal of endourology","volume":" ","pages":"S21-S28"},"PeriodicalIF":2.9000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MRI Fusion Cryoablation: Is There an Outcome Difference Between Anterior and Posterior Lesions?\",\"authors\":\"Lara Rodriguez-Sanchez, Sonya A Lehmann, Michael W Kattan, Alberto Lopez-Prieto, Luis Avila-Moreno, Gloria Egui-Benatuil, Fernando J Bianco\",\"doi\":\"10.1089/end.2024.0720\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Introduction:</i></b> Cryotherapy pioneered ablation therapy for prostate cancer (PCa), initially using larger ablations. As the technique advanced, a more targeted approach was developed irrespective of lesion location. However, some clinical guidelines have addressed concerns for treating posterior areas. This study evaluates the validity of these concerns. <b><i>Materials and Methods:</i></b> We retrospectively studied 814 Magnetic Resonance Imaging Fusion Target Cryotherapy (MRFTC) treatment-naïve patients with PCa with a single index lesion (2013-2023) under local anesthesia. We grouped by treatment location: anterior, anterior-posterior, and posterior. Disease progression, defined as conversion to radical treatment, initiation of hormonal therapy, or development of metastases, was evaluated with survival analysis via the Kaplan-Meier log-rank test. Univariate and multivariable analyses were employed to compare outcomes among different treatment groups and other risk factors. Functional outcomes were evaluated using the Sexual Health Inventory for Men (SHIM) and International Prostate Symptom Score questionnaires, with comparisons made over time and by lesion location through <i>t</i>-tests. Complication rates were documented across the various treatment areas. <b><i>Results:</i></b> The distribution of patients' characteristics across treatment groups was similar. Procedure pain scores were similar irrespective of lesion location. Five years post-MRFTC, 87%, 89%, and 90% of patients treated for anterior, anterior-posterior, and posterior lesions, respectively, remained progression-free with no significant variation between groups (<i>p</i> = 0.22). For all groups, there were significant improvements in urinary function (baseline vs. 3 months). The posterior group showed a marginal, yet statistically significant negative difference in SHIM scores at 3 months. However, the score recovered by 1 year where no additional significant changes were noted. The most common complication was urinary retention and no cases of rectal fistula were reported. <b><i>Conclusions:</i></b> Our findings challenge clinical guidelines suggesting avoidance of focal cryoablation for posterior lesions. Using MRFTC, cryotherapy has proven to be safe and effective, regardless of lesion location.</p>\",\"PeriodicalId\":15723,\"journal\":{\"name\":\"Journal of endourology\",\"volume\":\" \",\"pages\":\"S21-S28\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of endourology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/end.2024.0720\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of endourology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/end.2024.0720","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/6 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

冷冻疗法开创了前列腺癌(PCa)的消融治疗,最初使用更大的消融。随着技术的进步,一种更有针对性的方法被开发出来,而不考虑病变的位置。然而,一些临床指南已经解决了治疗后部区域的问题。本研究评估了这些担忧的有效性。材料和方法:我们回顾性研究了814例局部麻醉下单指数病变PCa患者磁共振成像融合靶冷冻治疗(MRFTC) treatment-naïve(2013-2023)。我们按治疗位置分组:前、前、后、后。疾病进展,定义为转向根治治疗,激素治疗的开始,或转移的发展,通过Kaplan-Meier对数秩检验的生存分析进行评估。采用单变量和多变量分析比较不同治疗组的结果和其他危险因素。使用男性性健康量表(SHIM)和国际前列腺症状评分问卷对功能结果进行评估,并通过t检验对不同时间和病变部位进行比较。在不同的治疗领域记录了并发症的发生率。结果:各治疗组患者特征分布相似。无论病变位置如何,手术疼痛评分相似。mrftc后5年,分别有87%、89%和90%的前、前、后病变患者无进展,组间无显著差异(p = 0.22)。所有组的泌尿功能均有显著改善(基线与3个月对照)。后置组在3个月时SHIM评分有明显的统计学差异。然而,1年后得分恢复,没有发现额外的显著变化。最常见的并发症是尿潴留,无直肠瘘病例报告。结论:我们的研究结果挑战了临床指南建议避免局灶性冷冻消融后路病变。使用MRFTC,冷冻疗法已被证明是安全有效的,无论病变位置如何。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
MRI Fusion Cryoablation: Is There an Outcome Difference Between Anterior and Posterior Lesions?

Introduction: Cryotherapy pioneered ablation therapy for prostate cancer (PCa), initially using larger ablations. As the technique advanced, a more targeted approach was developed irrespective of lesion location. However, some clinical guidelines have addressed concerns for treating posterior areas. This study evaluates the validity of these concerns. Materials and Methods: We retrospectively studied 814 Magnetic Resonance Imaging Fusion Target Cryotherapy (MRFTC) treatment-naïve patients with PCa with a single index lesion (2013-2023) under local anesthesia. We grouped by treatment location: anterior, anterior-posterior, and posterior. Disease progression, defined as conversion to radical treatment, initiation of hormonal therapy, or development of metastases, was evaluated with survival analysis via the Kaplan-Meier log-rank test. Univariate and multivariable analyses were employed to compare outcomes among different treatment groups and other risk factors. Functional outcomes were evaluated using the Sexual Health Inventory for Men (SHIM) and International Prostate Symptom Score questionnaires, with comparisons made over time and by lesion location through t-tests. Complication rates were documented across the various treatment areas. Results: The distribution of patients' characteristics across treatment groups was similar. Procedure pain scores were similar irrespective of lesion location. Five years post-MRFTC, 87%, 89%, and 90% of patients treated for anterior, anterior-posterior, and posterior lesions, respectively, remained progression-free with no significant variation between groups (p = 0.22). For all groups, there were significant improvements in urinary function (baseline vs. 3 months). The posterior group showed a marginal, yet statistically significant negative difference in SHIM scores at 3 months. However, the score recovered by 1 year where no additional significant changes were noted. The most common complication was urinary retention and no cases of rectal fistula were reported. Conclusions: Our findings challenge clinical guidelines suggesting avoidance of focal cryoablation for posterior lesions. Using MRFTC, cryotherapy has proven to be safe and effective, regardless of lesion location.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of endourology
Journal of endourology 医学-泌尿学与肾脏学
CiteScore
5.50
自引率
14.80%
发文量
254
审稿时长
1 months
期刊介绍: Journal of Endourology, JE Case Reports, and Videourology are the leading peer-reviewed journal, case reports publication, and innovative videojournal companion covering all aspects of minimally invasive urology research, applications, and clinical outcomes. The leading journal of minimally invasive urology for over 30 years, Journal of Endourology is the essential publication for practicing surgeons who want to keep up with the latest surgical technologies in endoscopic, laparoscopic, robotic, and image-guided procedures as they apply to benign and malignant diseases of the genitourinary tract. This flagship journal includes the companion videojournal Videourology™ with every subscription. While Journal of Endourology remains focused on publishing rigorously peer reviewed articles, Videourology accepts original videos containing material that has not been reported elsewhere, except in the form of an abstract or a conference presentation. Journal of Endourology coverage includes: The latest laparoscopic, robotic, endoscopic, and image-guided techniques for treating both benign and malignant conditions Pioneering research articles Controversial cases in endourology Techniques in endourology with accompanying videos Reviews and epochs in endourology Endourology survey section of endourology relevant manuscripts published in other journals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信